S/N 10/667,208 PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dennis A. Carson et al. Examiner: Amy A. Lewis

Serial No.: 10/667,208 Group Art Unit: 1614

Filed: September 19, 2003 Docket: 103.032US1

Title: USE OF ETODOLAC TO TREAT HYPERPLASIA

DEC 1 2 7005

## INFORMATION DISCLOSURE STATEMENT

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicants believe that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicants have not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicants respectfully request that notice of such requirement be directed to Applicants' below-signed representative. Applicants acknowledge the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

## INFORMATION DISCLOSURE STATEMENT

Serial No:10/667,208

Filing Date: September 19, 2003

Title: USE OF ETODOLAC TO TREAT HYPERPLASIA

Page 2 Dkt: 103.032US1

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

DENNIS A. CARSON ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6968

Date December 7, 2005

William F. Prout Reg. No. 33,995

<u>CERTIFICATE UNDER 37 CFR 1.8:</u> The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 7<sup>th</sup> day of December, 2005.

Jonathan Ferguson Name

Signature

PTO/S8/08A(10-01)
Approved for use through 10/31/2002, 0MB 651-0031
US Patent & Trademerk Office: U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE 10/667,208 **Application Number** STATEMENT BY APPLICANT September 19, 2003 Filing Date Carson, Dennis **First Named Inventor Group Art Unit** 1614 DEC 12 7005 Lewis, Amy **Examiner Name** Attorney Docket No: 103.032US1 Sheet 1 of 1

	US PATENT DOCUMENTS							
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate				
	US-2005/0239752A1	10/27/2005	Carson, D. A., et al.	12/16/2004				
	US-4,041,169	08/09/1977	Demerson, C. A., et al.	10/28/1976				
<del></del>	US-4,179,503	12/18/1979	Asselin, A. A., et al.	05/08/1978				
	US-5,780,435	07/14/1998	Garnick, M. B., et al.	12/15/1995				
	US-6,300,313	10/09/2001	Engel, J., et al.	09/22/1999				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T²			
	CA-1299577	04/28/1992	Guindon, Y., et al.				
	GB-1436893	05/26/1976	Shering Aktiengesellschaft et al.				
	WO-02/02125A1	01/10/2002	Tait, R., et al.				

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		MYCEK, M. J., et al., "Anticancer Drugs", <u>Lippincott's Illustrated Reviews:</u> <u>Pharmacology, Second Edition</u> , (1997),373; 387-395	